Industry Satellite Symposia
Switch To Module
ESMO Congress 2021 - Conference Calendar
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Digital Evaluations
Everything
Everything
Session Title
Session Number
Presentation Title
Presentation Number
Author
Presenter
Chair
Filter By
Day
Select All
Deselect All
Fri, 17.09.2021
12
Sat, 18.09.2021
11
Sun, 19.09.2021
12
Mon, 20.09.2021
11
Tue, 21.09.2021
11
Room
Select All
Deselect All
Channel 3
14
Channel 4
15
Channel 5
13
Channel 6
15
Session Type
Select All
Deselect All
Industry Satellite Symposium
57
Presentation Type
Select All
Deselect All
Invited Speaker
57
Presentation Topic
Select All
Deselect All
General interest
57
Cancel
Clear
Search
Advanced Search
Sign in
Scheduled sessions
On-demand Educational sessions
On-demand Special Symposia
On-demand Multidisciplinary sessions
On-demand ePosters
Industry Satellite Symposia
Final Programme PDF
Browsing Over 57 Sessions
Sort By
Upcoming First
Upcoming First
Relevance
Session Number
Session Datetime
Advanced Accelerator Applications, a Novartis Company - Cutting through the noise: How do GEP-NET patients stand to benefit from PRRT?
(ID 137)
Time
08:45 - 10:15
Myriad Genetics - Developments in precision medicine for breast and ovarian cancers
(ID 136)
Time
08:45 - 10:15
Advanced Accelerator Applications, a Novartis Company - Actionable Targets in Advanced Prostate Cancer: The Potential of Molecular Profiling and Radioligand Therapy
(ID 141)
Time
10:30 - 12:00
Ipsen - Spotlight on emerging therapies: Multidisciplinary discussions (advanced RCC, HCC and DTC)
(ID 138)
Time
10:30 - 12:00
AstraZeneca - Emerging immuno-oncology options in metastatic NSCLC and SCLC: Clinical evidence and future perspectives
(ID 140)
Time
10:30 - 12:00
Novartis - Staying on Track: Translating Evidence to Practice in Melanoma
(ID 139)
Time
10:30 - 12:00
Sanofi Genzyme - Optimizing Immuno-oncology in NSCLC: What Do We Know and Where Should We Go?
(ID 144)
Time
18:45 - 20:15
Bristol Myers Squibb - I-O Revolution: New Perspectives in the Treatment of Thoracic Cancers
(ID 143)
Time
18:45 - 20:15
Gilead Sciences Europe Ltd. - Triple-Negative Breast Cancer: : See Beyond the Negatives
(ID 145)
Time
18:45 - 20:15
AstraZeneca - Mapping pathways for PARP inhibition in prostate cancer: practical considerations for clinical practice
(ID 142)
Time
18:45 - 20:15
Bristol Myers Squibb - Shaping Tomorrow Today: What Does the Future Hold for Melanoma?
(ID 146)
Time
08:45 - 10:05
Boston Scientific - Expanding the treatment options for colorectal liver metastases with Y-90 radioembolisation: results of EPOCH study
(ID 149)
Time
08:45 - 10:15